Research Report

Author

李曉然小姐(Margaret Li)
分析師

本科主修市場行銷和英語,並於香港浸會大學獲得經濟學碩士學位。現為輝立証券持牌分析師,主要負責能源和公用事業等板塊的研究。曾在大型銀行、券商和資產管理公司工作,對於期貨和大宗商品衍生品領域擁有銷售、研究分析和市場推廣等工作經驗。

Margaret, a holder of a Bachelor`s degree in Marketing and English and a Master`s degree in Applied Economics from Hong Kong Baptist University, is currently employed as a licensed analyst at Phillip Securities. She specializes in conducting research focusing on the energy and utilities sectors. Prior to her current position, Margaret gained valuable work experience in a large bank, securities firm, and asset management companies. Her expertise lies in sales, research analysis, and marketing within the fields of futures and commodities derivatives.


Phone: 22776535  
Email Enquiry For Research Report and Business enquiry

CHICMAX (2145.HK) Profit Alert Demonstrates Resilience, Multi-Brand Portfolio Entering Harvest Phase

Thursday, March 12, 2026 Views604
CHICMAX(2145)
Recommendation on  12 March 2026
Recommendation Buy
Price on Recommendation Date $58.300
Target Price $78.640

Overview

CHICMAX is a research-driven, multi-brand leader in the cosmetics industry. Founded in 2002, the company owns three core brands—KANS, ONE LEAF, and Baby Elephant—and has successfully established new growth drivers such as newpage and ARMIYO. It operates across four major segments: skincare, hair care, maternal and infant products, and cosmetics, with two self-built R&D centers and two supply chains worldwide. The flagship brand, KANS, achieved revenue exceeding RMB 5.5 billion in 2024, ranking as the No. 1 beauty brand on Douyin for the second consecutive year.

Performance review

The company has issued a positive profit alert, estimating that (i) in 2025, the company's revenue will be approximately RMB 9.1 billion to RMB 9.2 billion, representing a year-on-year increase of about 34.0% to 35.4%; and net profit will be approximately RMB 1.14 billion to RMB 1.16 billion, representing a year-on-year increase of about 41.9% to 44.4%. The increase in revenue and profit is primarily attributable to the successful implementation of the company's multi-brand and multi-category strategy, the continued revenue growth of its science-backed anti-aging skincare brand, KANS, and a significant year-on-year revenue increase from its Chinese efficacy skincare brand for infants and children, newpage.

In the first half of 2025, the company's revenue reached a new high of RMB 4.11 billion with a year-on-year increase of 17.3%; net profit attributable to the parent company amounting to RMB 556 million with a year-on-year increase of 34.7%; EPS was RMB 1.32 with a year-on-year increase of 30.7%. The company declared an interim dividend of RMB 0.5 per share, and the cumulative dividend payout since its listing has exceeded RMB 1.2 billion, maintaining a sustained high dividend payout ratio. For January 2026, the company's combined Gross Merchandise Volume (GMV) across the Douyin channel reached approximately RMB 660 million with a year-on-year increase of 9%, among which, KANS's GMV was approximately RMB 530 million with a year-on-year decrease of 3%; New Page's GMV was approximately RMB 70 million with a year-on-year increase of 120%; KYOCA and ATISER achieved a GMV of RMB 10 million respectively with rapid year-on-year growth; ARMIYO's GMV was approximately RMB 30 million with a year-on-year increase of 267%.

Figure 1:Operating income growth rate

"Figure

Resources: Annual report, Phillip Securities

Figure 2:Dividend Payout Ratio

"Figure

Resources: Annual report, Phillip Securities

The flagship brand KANS's performance is eye-catching

According to Qingyan Intelligence, in 2025, the GMV of cosmetics on the Douyin channel grew by more than 16% year-on-year, with market share increasing by 2.6 percentage points. By brand nationality, domestic brands held a market share of 65.9%, occupying a dominant position. KANS, with over RMB 8 billion in GMV, continued to rank first among Douyin cosmetics brands, at a leading position, and maintained high growth momentum with over 20% growth rate. As of September 1, 2025, the cumulative sales of the hit product Polypeptide Collagen Softening exceeded 16.5 million sets, it is popular among consumers. The age of KANS' user portrait is mainly concentrated in the young group of 18-35 years old, accounting for as high as 73.09%, indicating that KANS' revenue growth is deeply bound with the young consumer group with skin care needs, and is expected to enjoy structural dividends. The main purchasers are concentrated in high-quality users in first - and second-tier cities (the top ten cities include Chongqing, Shanghai, Chengdu, Beijing, Guangzhou, Shenzhen, Suzhou, Xi'an, Dongguan and Hangzhou). We believe that users in first - and second-tier cities generally have higher incomes, stronger consumption resilience, and are relatively less price-sensitive, which may lay the foundation and channel cognition for KANS to launch high-end series in the future. In January 2026, the GMV of the beauty category on Douyin increased by 11.1% month-on-month, indicating that the festival scene has a significant pulling effect on cosmetic consumption. KANS topped the list again with a GMV of over RMB 300 million. To sum up, we believe that KANS has established a strong brand momentum, not only with a large market share (top of GMV), but also with a high-quality user structure, which can effectively resist the impact of competitive products and transcend the consumption cycle. In addition, in February this year, KANS' New One store officially opened. This is KANS' first directly operated offline concept store in its 23 years of establishment. We think it is a milestone step for the brand. KANS is currently the only domestic skin care brand in the core position of New One Stores. This move demonstrates KANS' strategic intention to enter the high-end market and compete with international first-line brands.

New Momentum Added to Multi-Brand Matrix

ATISER Accelerates Its Breakout
In July 2025, the company launched a new skincare brand, ATISER, focusing on skin radiance and anti-aging, translating clinical aesthetic outcomes into daily skincare routines. Its core product, the M22, was developed in collaboration with Shanghai Ninth People's Hospital. Infused with PDRN, it is hailed as a "fine line savior and brightening master," suitable for sensitive skin, delivering deep hydration, firming, and repair. The brand made its livestream debut on Douyin on the channel of Wei Xue, a top beauty influencer. According to Chanmama data, ATISER achieved a GMV of over RMB 6 million in July. By August, it accelerated its breakout, surpassing RMB 50 million in GMV. ATISER 's success is no accident—it reflects the company’s dual-engine strategy of "R&D + marketing." It demonstrates the company’s ability to rapidly develop market-fit products based on consumer needs, while leveraging precise KOL collaborations to achieve brand synergy. This 0-to-1 rapid-launch capability is precisely the core competitive moat of CHICMAX in multi-brand operations.

China's first playful functional maternal & baby brand launched
Anpanman (baby and childcare), established in 2025, is the first playful functional maternal and baby brand in China under the Anpanman IP. The brand combines Anpanman's rich IP story elements and childlike designs to create a unique playful care experience for babies. Its product range includes face care, personal care, and home care series. Anpanman is a childhood memory spanning multiple generations. As of 2024, the total cumulative revenue from the Anpanman IP reached USD 60 billion, ranking sixth globally. We believe that Anpanman's deeply rooted image of "bravery, protection, warmth, and positivity" naturally aligns with the brand's philosophy of accompanying babies in their daily lives and helping them fearlessly navigate the outside world, creating a distinct co-branding differentiation in the market. The product packaging features the highly endearing Anpanman design, evoking instant emotional resonance among consumers through its adorable appeal. This effectively lowers the barrier to purchase decisions and enhances conversion rates at the point of sale.

Valuation and Investment Recommendation

According to data from the National Bureau of Statistics, the total retail sales of consumer goods in China exceeded RMB 50 trillion for the first time in 2025, reaching RMB 50,120.2 billion with a year-on-year increase of 3.7%. Consumption contributed 52% to economic growth, indicating stable expansion driven by policies aimed at boosting domestic demand. Retail sales of cosmetics in China also showed steady growth, increasing from RMB 204.94 billion in 2015 to RMB 435.65 billion in 2024, representing a CAGR of approximately 10.5%. Over the decade, cosmetics' share of the overall consumer market expanded from 1.5% in 2015 to 2.5% in 2024, confirming the increasingly critical role of cosmetic consumption in the structure of resident spending. Transitioning from reliance on a single brand to building a multi-brand matrix, the company's strategic transformation delivered results exceeding expectations in 2025, validating the feasibility of its new strategy. In the future, by replicating the successful paths of KANS and Newpage, more sub-brands are poised to become new engines for the company's growth. Amidst the rise of domestic brands and the consumption recovery, CHICMAX, already a frontrunner, is leveraging the core competitiveness of its multi-brand strategy to advance into a higher-tier market. We forecast the company's operating revenue to be RMB 9.15 billion, RMB 11.44 billion, and RMB 13.72 billion in 2025, 2026, and 2027 respectively, with EPS of RMB 2.89, 3.46, and 4.14, corresponding to P/E ratios of 17.7x, 14.8x, and 12.4x. We assign a target price of 78.64 HKD, based on 20x expected 2026 P/E, and upgrade the rating to "Buy." (Current price as of 12 Mar)

Risk factors

Downward macroeconomic situation, intensified industry competition, management changes, and new product promotion failing to meet expectations.

Financial

"Financial"
"PHILLIP

Current Price as of: 12 Mar
Exchange rate: HKD/RMB = 0.88
Source: PSHK Est.

Download PDF version

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
新闻稿
E-Check
Login
Investor Notes
Free Subscribe
Contact Us